Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period

Key Takeaways Merck projects over $70B in pipeline opportunities by mid-2030s beyond the Keytruda LOE.MRK's Capvaxive, Winrevair and Welireg delivered solid 2025 sales amid strong ongoing launches.Merck's phase III pipeline has nearly tripled since 2021, aided by M&A and new approvals.Merck (MRK) announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both earnings and sales. Importantly, on the fourth-quarter conference call, management provided an enco ...